Text Size

GLP-2 (Glucagonlike Peptide-2) and Blood Flow

This study has been completed.
Sponsor:
Information provided by:
Glostrup University Hospital, Copenhagen
ClinicalTrials.gov Identifier:
NCT00540215
First received: October 4, 2007
Last updated: February 10, 2011
Last verified: October 2007
History of Changes
  Purpose

It is the study aim to investigate the effect of glp-2 on blood flow in humans. we wish to study eventual changes in renal blood flow, carotic blood flow and cardiac out put.

GLP-2 will be administered subcutaneously, and the effect monitored by doppler ultra sound scannings and cotinuesly measuring of cardiac out put and blood pressure.

The study will include 15 healhty volunteers, 10 wil receive 450 nmol GLP-2 and 5 will receive 1 ml of isotonic saline (as baseline reference).


Condition Intervention
Regional Blood Flow
 Other: Glucagonlike peptide

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: Single Blind (Subject)
Primary Purpose: Basic Science
Official Title: The Role of GLP-2 in Univercal Changes in Blood Flow in Humans

Resource links provided by NLM:

Drug Information available for: Glucagon
U.S. FDA Resources

Further study details as provided by Glostrup University Hospital, Copenhagen:

Primary Outcome Measures:
  • effect of glp-2 [ Time Frame: during study ]

Secondary Outcome Measures:
  • potential new ideas for further studies [ Time Frame: months to years ]

Enrollment: 15
Study Start Date: October 2007
Study Completion Date: February 2008
Primary Completion Date: January 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Active Comparator: 1
450 nmol GLP-2 SC
 Other: Glucagonlike peptide
450 nmol native form, synthetic
Placebo Comparator: 2
1 ml isotonic saline SC
 Other: Glucagonlike peptide
450 nmol native form, synthetic

Detailed Description:

se the above

  Eligibility

Ages Eligible for Study:   20 Years to 60 Years
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • Age 20-60
  • Healthy
  • No medication
  • Not pregnant

Exclusion Criteria:

  • All of the persons not meeting the abowe mentioned criteria
  Contacts and Locations
Please refer to this study by its ClinicalTrials.gov identifier: NCT00540215

Locations
Denmark
Glostrup University Hospital
Glostrup, Region Hovedstaden, Denmark, 2600
Sponsors and Collaborators
Glostrup University Hospital, Copenhagen
Investigators
Principal Investigator: lasse bremholm, MD Glostrup university hospital
  More Information

No publications provided

ClinicalTrials.gov Identifier: NCT00540215     History of Changes
Other Study ID Numbers: H-D-2007-0050
Study First Received: October 4, 2007
Last Updated: February 10, 2011
Health Authority: Denmark: The Regional Committee on Biomedical Research Ethics

Additional relevant MeSH terms:
Glucagon
Glucagon-Like Peptide 1
Hormones
Hormones, Hormone Substitutes, and Hormone Antagonists
Physiological Effects of Drugs
 Pharmacologic Actions
Gastrointestinal Agents
Therapeutic Uses
Incretins

ClinicalTrials.gov processed this record on May 16, 2013